Results add to data suggesting that SVR can be achieved with the combination of daclatasvir (BMS-790052) and asunaprevir (BMS-650032) in HCV genotype 1b patients Study expanded to include alfa/RBV ineligible or intolerant patients Bristol-Myers Squibb Company (NYSE: BMY) announced results from...
Bristol-Myers Squibb Company (NYSE: BMY) and sanofi-aventis (EURONEXT: SAN, NYSE: SNY) announced that the United States Food and Drug Administration (FDA) has granted the companies an additional six-month period of exclusivity to market PLAVIX® (clopidogrel bisulfate). Exclusivity for PLAVIX in...
The American Pharmacists Association (APhA) Foundation announced it has been selected as an initial grantee in and will play a major role in the new Together on Diabetes®: Communities Uniting to Meet America's Diabetes Challenge. The $100 million initiative, funded by the Bristol-Meyers Squibb...
Bristol-Myers Squibb Company (NYSE: BMY) and the ADAP Crisis Task Force (ACTF) announced an enhanced agreement to support the efforts of AIDS Drug Assistance Programs (ADAPs) to provide antiretroviral medicines to people living with HIV and AIDS. Building on an agreement signed in March of...
Facet Biotech Corporation (NASDAQ: FACT) and Bristol-Myers Squibb Company (NYSE: BMY) announced that potentially promising data from a Phase I/II study of elotuzumab, an investigational humanized antibody being studied for the treatment of relapsed multiple myeloma (MM), were presented at the...